BPC 157 for Acute Hamstring Muscle Strain Repair
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pentadecapeptide BPC 157, Placebo.
- Who it may be relevant to
- Registry conditions: Hamstring Muscle Strain, Skeletal Muscle Injury. Basic parameters: 18 years — 45 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI
Overview
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Detailed description
Acute hamstring strains are common in running- and field-based sports and often lead to prolonged time away from sport and a risk of recurrence. Preclinical research suggests that BPC 157 may influence pathways involved in tissue protection, angiogenesis, and repair. Human clinical evidence remains limited, so a controlled trial is needed to evaluate potential benefits and characterize safety in a musculoskeletal injury population. After screening and baseline assessments (including MRI confirmation of an acute grade II hamstring strain), eligible participants will be randomized 1:1 to receive subcutaneous BPC 157 or matching placebo once daily for 14 days. All participants will follow the same evidence-based rehabilitation protocol supervised by study physiotherapists. Clinical assessments will occur at Days 3, 7, 14, 28, and 56, with additional follow-up at 3 months after return-to-play for recurrence monitoring. Safety will be assessed through adverse event monitoring, vital signs, and standard laboratory tests. An independent Data and Safety Monitoring Committee will review unblinded safety data at predefined intervals.
Interventions
- Drug Pentadecapeptide BPC 157
subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days. - Drug Placebo
subcutaneous injection (administered by trained study staff). Schedule: once daily for 14 days.
Primary outcome measures
- Time to return to unrestricted sport participation (days) [Time frame: 8 Weeks]
- Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review. [Time frame: 14 Days]
Secondary outcome measures (3)
- Change in pain during activity on a 0-10 Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain). [Time frame: 56 Days]
- Hamstring strength limb symmetry index (LSI) by isokinetic dynamometry [Time frame: 56 Days]
- Change in Lower Extremity Functional Scale (LEFS; 0-80, higher scores indicate better function) [Time frame: 56 Days]
Eligibility criteria
Inclusion criteria
- Age 18 to 45 years.
- Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening.
- MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion.
- Pre-injury physical activity >= 3 sessions/week or participation in organized recreational sport.
- Willingness to follow the standardized rehabilitation protocol and attend all study visits.
- For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose.
Exclusion criteria
- Grade III hamstring tear, tendon avulsion, or injury requiring surgical management.
- Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment.
- Prior hamstring strain on the index limb within the past 6 months.
- Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening.
- Known bleeding disorder or current therapeutic anticoagulation.
- Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk.
- Known allergy or hypersensitivity to components of the investigational product or placebo.
- Pregnant or breastfeeding.
- Current participation in another interventional clinical study or participation within 30 days prior to screening.
- Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Peking University Shenzhen Hospital — Shenzhen
Identifiers
NCT: NCT07437547 · BH-BPC157-MUSC-001